SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Aptinyx Inc. APTX NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Analyst Price Target

Aptinyx Inc. (APTX) is a Biotechnology company in the Healthcare sector, currently trading at $0.10. It has a SharesGrow Score of 43/100, indicating a mixed investment profile with 1 out of 7 criteria passed.

Analyst consensus target is APTX = $1 (+941.7% upside).

Net income is $65M (loss), growing at -8.2%/yr. Net profit margin is 0% (thin). Gross margin is 100% (+0 pp trend).

Balance sheet: total debt is $25M against $38M equity (Debt-to-Equity (D/E) ratio 0.65, moderate). Current ratio is 10.18 (strong liquidity). Debt-to-assets is 37.3%. Total assets: $67M.

Analyst outlook: 2 / 8 analysts rate APTX as buy (25%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 50/100 (Partial), Moat 46/100 (Partial), Future 52/100 (Partial), Income ?/100 (Fail).

$1.00

▲ 941.67% Upside

Average Price Target

The 12-month price target for Aptinyx Inc. is $1.00.

APTX SharesGrow Score Overview

53/100

SharesGrow Score

Mixed signals — some strengths

View full scorecard →

VALUE 100/100

Valuation — P/E, PEG, Forward PEG

GROWTH 15/100

Financials — average growth

PAST 0/100

strong — trend

HEALTH 50/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 46/100

Gross margin is + market cap

FUTURE 52/100

Analyst outlook — as buy

INCOME 0/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — APTX

APTX trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $1, implying +941.7% from the current price $0. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.

View details →

APTX: -64.5%/yr revenue is, -8.2%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

No analyst coverage available for this stock.

Balance sheet APTX: Debt-to-Equity (D/E) ratio 0.65 (moderate), Current ratio is 10.18 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

APTX: Gross margin is 100% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 46/100. ≥ 70 = Pass.

View details →

Analyst outlook: 2 / 8 analysts rate APTX as buy (25%). Analyst consensus target is $1 (+941.7% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

No analyst coverage available for this stock.

Stock Chart & Stats

Market Data

52-Week Range0.009-0.72

Volume231.13K

Avg Volume (30D)132.92K

Beta (1Y)1.22

Share Statistics

EPS (TTM)-0.95

Shares Outstanding$67.72M

IPO Date2018-06-21

Employees12

CEOCraig R. Jalbert CIRA

Financial Highlights & Ratios

EBITDA$-61.71M

Net Income$-64.85M

Operating Income$-62.57M

Total Cash$56.21M

Total Debt$24.9M

Net Debt$-31.3M

Total Assets$66.68M

Price / Earnings (P/E)-0.1

Analyst Forecast

1Y Price Target$1.00

Target High$1.00

Target Low$1.00

Upside+941.7%

Rating ConsensusHold

Analysts Covering8

Buy 25% Hold 63% Sell 13%

Price Target Summary

Company Info

CountryUS

ExchangeNASDAQ Global Select

CurrencyUSD

ISINUS03836N1037

Price Chart

APTX

Aptinyx Inc. ↗ · NASDAQ Global Select

Healthcare • Biotechnology

0.01 52WK RANGE 0.72

People Also View

Nuvation Bio Inc.

CytomX Therapeutics, Inc.

Assembly Biosciences, Inc.

Spero Therapeutics, Inc.

Achilles Therapeutics plc

Instil Bio, Inc.

Aileron Therapeutics, Inc.

Magenta Therapeutics, Inc.

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message